Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adverse event reports electronic submissions expected by spring on limited basis -- FDA.

This article was originally published in The Tan Sheet

Executive Summary

PAPERLESS ADVERSE EVENT REPORT SUBMISSIONS EXPECTED BY SPRING from several companies under an ongoing pilot program of FDA's Adverse Event Reporting System (AERS), FDA Surveillance and Data Processing Branch Chief Bill Calvert said at the Nonprescription Drug Manufacturers Association Research & Scientific Development Conference in Washington, D.C. Nov. 13-14. Calvert's office is overseeing agency efforts to implement the transition from "paper" adverse event reports to electronic reports.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel